OverviewChartNewsTraderScreen

HSBC WAR. CALL 12/25 SNW/  DE000HS3VNS5  /

gettex Zettex2
5/17/2024  9:35:03 PM Chg.-0.0100 Bid9:59:47 PM Ask9:59:47 PM Underlying Strike price Expiration date Option type
0.6000EUR -1.64% 0.6100
Bid Size: 10,000		 0.6200
Ask Size: 10,000		 SANOFI SA INHABER ... 100.00 EUR 12/19/2025 Call
GlobeNewswire 5/17 Recludix Pharma Presents Data Demonstrating Oral STAT3 Inhibitors Drive Differentiated Efficacy and ...
GlobeNewswire 5/13 Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 20...
GlobeNewswire 5/13 Fulcrum Therapeutics Enters into a Collaboration and License Agreement with Sanofi for the Developme...
TeleTrader 5/13 Europe mixed at open as CPI prints loom
GlobeNewswire 5/13 Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of Adolescents with Chroni...
TeleTrader 5/10 Novavax skyrockets 213.5% in premarket, highest in 16 months
TeleTrader 5/10 Novavax soars 39.6% in premarket after Sanofi license deal
GlobeNewswire 5/10 Press Release: Sanofi and Novavax announce co-exclusive licensing agreement to co-commercialize COVI...
GlobeNewswire 5/9 Royalty Pharma to Acquire Royalty Interest in Sanofi’s Frexalimab
TeleTrader 5/9 Europe opens mixed with BoE in focus
GlobeNewswire 5/8 IGM Biosciences Announces First Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewswire 5/7 Denali Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights
GlobeNewswire 5/2 Regeneron Reports First Quarter 2024 Financial and Operating Results
GlobeNewswire 5/2 Press Release: Beyfortus real-world evidence published in The Lancet shows 82% reduction in infant R...
GlobeNewswire 4/30 Press Release: Annual General Meeting of April 30, 2024
TeleTrader 4/25 Europe opens mostly down after corporate earnings
TeleTrader 4/25 Europe down in premarket as financial results pour in
TeleTrader 4/25 Sanofi books net sales of €10.5B in Q1, up 2.4%
GlobeNewswire 4/25 Press Release: Sanofi Q1: robust 7% sales growth driven by launches, underpins full-year guidance
GlobeNewswire 4/23 Press Release: Rilzabrutinib LUNA 3 phase 3 study met primary endpoint in immune thrombocytopenia
GlobeNewswire 4/17 IGM Biosciences Announces Refocusing of Sanofi Collaboration
GlobeNewswire 4/17 Press Release: New 48-week frexalimab phase 2 data support potential for high sustained efficacy in ...
GlobeNewswire 4/16 2024 DTA Summit Agenda is LIVE!!
GlobeNewswire 4/10 Nurix Therapeutics Reports First Quarter Fiscal 2024 Financial Results and Provides a Corporate Upda...
GlobeNewswire 4/9 Nurix Therapeutics Announces Extension of Strategic Collaboration with Sanofi to Develop Novel Targe...